Base-Modified Cytidine Nucleotides for Cytarabine-Resistant Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for leukemia, myelodysplastic syndromes, and lymphomas are often intolerable and ineffective, particularly in elderly patients with cytarabine resistance, lacking a chemotherapeutic option with a better toxicity profile and efficacy against common resistance mechanisms.
Innovation Solution
Development of novel base-modified cytidine nucleotides, specifically compounds of formula I, IA, and IB, or their pharmaceutically acceptable salts, for parenteral administration, which exhibit a favorable efficacy-toxicity balance and retain activity against cytarabine resistance mechanisms, such as increased cytidine deaminase expression and reduced deoxycytidine kinase expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies (e.g., cytarabine) are used for leukemia treatment, then treatment efficacy is achieved, but toxicity and intolerance increase particularly in elderly patients with cytarabine resistance
Solution Approach 1:
The patent modifies the chemical structure of cytidine nucleotides by changing parameters such as the sugar moiety (e.g., arabinose instead of ribose), base modifications (e.g., 5-fluoro, 5-methyl), and phosphate group configurations. These parameter changes create novel compounds (e.g., clofarabine, decitabine) that overcome cytarabine resistance mechanisms while maintaining therapeutic efficacy and reducing toxicity in elderly patients.
Solution Approach 2:
The invention creates composite nucleotide structures combining different sugar moieties, base modifications, and phosphate groups to form hybrid molecules with enhanced properties. Examples include compounds with arabinose sugar combined with fluorinated or methylated pyrimidine bases, creating molecules that simultaneously achieve high efficacy against leukemia cells and reduced harmful effects.
2Reliability
If cytarabine resistance mechanisms (increased cytidine deaminase expression, reduced deoxycytidine kinase expression) are present, then treatment failure occurs, but no effective alternative is available
Solution Approach 1:
The patent systematically modifies the chemical parameters of cytidine nucleotides to circumvent resistance mechanisms. By changing the sugar configuration to arabinose or modifying the base with fluorine or methyl groups, the compounds evade degradation by cytidine deaminase and overcome reduced deoxycytidine kinase expression, thereby maintaining activity against resistant leukemia cells.
Solution Approach 2:
The invention creates structural analogs and analogues of cytarabine that copy its therapeutic mechanism but with modified molecular features that resist degradation. These copies (e.g., clofarabine, decitabine) replicate the DNA incorporation capability while resisting the specific enzymatic degradation pathways that cause cytarabine resistance.
3Ease of operation
If existing chemotherapeutic options are used, then treatment is provided, but the toxicity profile makes them intolerable for many patients
Solution Approach 1:
By modifying chemical parameters such as introducing arabinose sugar moieties or fluorinated bases, the patent creates compounds with improved pharmacokinetic properties and reduced off-target effects. These parameter changes result in better tolerability profiles while preserving the essential anticancer activity, making the treatments more acceptable to patients and their caregivers.
Data Source
AI summary
Compounds of the formula Iwherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.